Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by Children's Hospital Boston.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Children's Hospital Boston
ClinicalTrials.gov Identifier:
NCT01263574
First received: December 17, 2010
Last updated: December 28, 2010
Last verified: December 2010
  Purpose

This study is designed to determine if the use of 70% ethanol lock solution in central lines decreases the rate of central line infections in children with short bowel syndrome. While ethanol locks have been used safely in children, there has been no published research to date that clearly shows it is of definite benefit in this group of patients.


Condition Intervention Phase
Catheter Related Infections
Short Bowel Syndrome
Drug: 70% ethanol
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by Children's Hospital Boston:

Primary Outcome Measures:
  • Catheter associated blood stream infection (CABSI). [ Time Frame: Number of infections reported per 1000 catheter days. ] [ Designated as safety issue: No ]
    Published data in intensive care unit (ICU) patients with CABSI has noted that central venous catheter cultures had a specificity of 98% and a negative predictive value of 97%. In our study, we will define CABSI as a positive central venous catheter blood culture in the face of clinical signs of infection, when the catheter has been used in the last 48 hours prior to infection, and without other obvious source of infection. CABSI rate will be reported as number of infections per 1000 catheter days after 12 months of follow up.


Estimated Enrollment: 48
Study Start Date: February 2011
Estimated Study Completion Date: September 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Heparinized Saline
This group will maintain their central lines patent with heparinized saline.
Drug: 70% ethanol
Administration of the lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards. The pre-measured volume of lock solution will then be injected into the catheter. The minimum dwell time of 4 hours will follow. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. On the other four days of the week, patients will receive heparin locks, per current standard of care. Volume of lock solution administered will be determined by catheter size.
Experimental: Ethanol lock solution group
Administration of the ethanol lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards
Drug: 70% ethanol
Administration of the lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards. The pre-measured volume of lock solution will then be injected into the catheter. The minimum dwell time of 4 hours will follow. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. On the other four days of the week, patients will receive heparin locks, per current standard of care. Volume of lock solution administered will be determined by catheter size.

  Eligibility

Ages Eligible for Study:   3 Months and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age >3 months
  • Intestinal failure patients
  • Silicone catheter for the administration of parenteral nutrition

Exclusion Criteria:

  • Age < 3 months
  • Weight < 5 kg
  • Documented allergy to ethanol
  • Evidence of tunnel site infection
  • Patients receiving continuous renal replacement therapy
  • Concomitant use of metronidazole
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01263574

Contacts
Contact: Tom Jaksic, M.D, Ph.D 617 355 9600
Contact: Christopher Duggan, M.D, MPH 617 355 9600

Locations
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Children's Hospital Boston
Investigators
Principal Investigator: Tom Jaksic, M.D, Ph.D Children's Hospital Boston
Principal Investigator: Christopher Duggan, M.D, MPH Children's Hospital Boston
  More Information

No publications provided

Responsible Party: Tom Jaksic, M.D, Ph.D, W. Hardy Hendren Professor of Surgery Surgical Director, Center for Advanced Intestinal Rehabilitation Vice-Chairman of Pediatric Surgery, Children's Hospital Boston
ClinicalTrials.gov Identifier: NCT01263574     History of Changes
Other Study ID Numbers: 09-03-0132
Study First Received: December 17, 2010
Last Updated: December 28, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Children's Hospital Boston:
Catheter related infections prevention/control
Anti infective agents
Catheter related infections prevention

Additional relevant MeSH terms:
Catheter-Related Infections
Communicable Diseases
Infection
Short Bowel Syndrome
Syndrome
Digestive System Diseases
Disease
Gastrointestinal Diseases
Intestinal Diseases
Malabsorption Syndromes
Pathologic Processes
Postoperative Complications
Ethanol
Pharmaceutical Solutions
Anti-Infective Agents
Anti-Infective Agents, Local
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014